Table 1.
List of all clinical trials of autophagy inhibitors in breast cancer.
| Phase | Clinical Trial | Treatment | Identifier |
|---|---|---|---|
| Unknown or Terminated or Withdrawn or Completed | |||
| 2 | Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients: a Pilot Study | Hydroxychloroquine |
NCT01292408 (Unknown status) 2012 |
| 1/2 | Phase I/II Study of Ixabepilone in Combination With the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients with Metastatic Breast Cancer | Ixabepilone and Hydroxychloroquine |
NCT00765765 (Terminated) 2013 |
| 2 | Phase Ib/II Study of Hydroxychloroquine in Metastatic ER-Positive Breast Cancer Progressing on Hormonal Therapy | Hydroxychloroquine in combination with hormonal therapy |
NCT02414776 (Terminated) 2015 |
| 1/2 | Preventing Invasive Breast Neoplasia with Chloroquine (PINC) Trial | High or low dose of Chloroquine |
NCT01023477 (Completed) 2016 |
| 2 | A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Trial Clinical and Correlative Effects of Chloroquine as a Novel Therapeutic Strategy in Breast Cancer | Chloroquine and placebo |
NCT02333890 (Unknown) 2016 |
| 1/2 | A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (“GLACIER”) | Gedatolisib or Hydroxychloroquine alone or in combination |
NCT03400254 (Withdrawn) 2020 |
| 2 | Phase II Study of The Efficacy and Safety of Chloroquine (C) in CombinAtion With Taxane or taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy | Chloroquine with taxane or taxane-like chemotherapy |
NCT01446016 (Completed) 2022 |
| Recruiting or Active | |||
| 1 | Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine Therapy in HR+/Her2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors | Abemaciclib with alternative dose of HCQ or Abemaciclib with both HCQ and endocrine therapy |
NCT04316169 (Recruiting) 2028 |
| 2 | A Phase II Pilot Trial of ABmacocliB or Abemaciclin and HydroxYchloroquine to Target Minimal Residual Disease in Brease Cancer Patients | Abemaciclib with or without Hydroxychloroquine |
NCT04523857 (Recruiting) 2028 |
| 2 | A Phase II Trial of Avelumab or Hydrochloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY) | HCQ alone, or Avelumab alone, or Avelumab with Palbociclib, or HCQ with Palbociclib |
NCT04841148 (Recruiting) 2028 |
| 1/2 | Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer | Hydroxycholoroquine, Letrozole, and Palbociclib |
NCT03774472 (Active) 2024 |
| 2 | CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | Hydroxychloroquine alone, or Everolimus alone, or the combination of hydroxychloroquine and Everolimus |
NCT03032406 (Recruiting) 2025 |